Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Market close flat in a short week
Thu, 17 Apr Closing

After a weak session yesterday, Indian equity markets began the day's proceedings on a positive note. The subsequent hours saw the indices scale higher as buying activity continued across index heavyweights. The momentum was maintained in the final trading hour as well and the indices closed well above the dotted line. While the BSE Sensex today closed higher by 352 points, the NSE-Nifty closed higher by 104 points. The BSE Mid Cap and BSE Small Cap also did well and notched gains of 1% each. Gains were largely seen in auto, banking and oil & gas stocks.

As regards global markets, Asian indices closed mixed today while the European indices have also opened mixed. The rupee was trading at Rs 60.39 to the dollar at the time of writing.

Most pharma stocks closed firm today with the key gainers being Cipla, Sun Pharma and Dr.Reddy's. As per a leading business daily, Dr.Reddy's has launched Eszopiclone drug in the US market post the approval received from the USFDA. Eszopiclone is the generic version of Lunesta and is used for the treatment of insomnia. Sunovion Pharmaceuticals Inc is the owner of the drug. According to IMS Health, Lunesta tablets and generics combined had US sales of about US$ 887 m for the 12 months ended January 2014. This is a positive for the company and will enhance its sales from the highly competitive US generics market. It must be noted that given the intense competition in the US market, Dr.Reddy's has put in place a strategy of not only launching new products but also focusing on those drugs that are in a niche category. Niche drugs typically have higher barriers to entry and so the competition and price erosion is not very high.

Telecom stocks closed in the positive today with the key gainers being Bharti Airtel and Idea Cellular. The Supreme Court (SC) has ruled that the books of any telecommunications company can be audited by the Comptroller and Auditor General of India (CAG), an order that has the potential to affect all private firms that pay the government to use public resources. According to the SC, the scrutiny by the government auditor is necessary to ensure the exchequer gets its legitimate share of the revenue generated from public resources. The apex court modified an earlier verdict of the Delhi high court that allowed the CAG to conduct statutory audit of only the telcos' revenue. India's telecom services firms had moved the Supreme Court in January on grounds that they were private companies and not under the jurisdiction of CAG, the public auditor tasked with auditing accounts of government agencies and schemes.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "Market close flat in a short week". Click here!


Related Views on News

GRANULES INDIA Share Price Up by 6%; BSE HEALTHCARE Index Up 2.7% (Market Updates)

May 5, 2021 | Updated on May 5, 2021

GRANULES INDIA share price is trading up by 6% and its current market price is Rs 354. The BSE HEALTHCARE is up by 2.7%. The top gainers in the BSE HEALTHCARE Index are GRANULES INDIA (up 6.0%) and LUPIN (up 11.9%). The top losers are PROCTER & GAMBLE HEALTH and SYNGENE INTERNATIONAL (down 0.1%).

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

Why Did Alembic Pharma Shares Fall Today? (Views On News)

May 5, 2021

Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider (Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps? (Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners (Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her? (Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?


India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms


May 5, 2021 (Close)